Cargando…
Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells
Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immunotherapie...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381771/ https://www.ncbi.nlm.nih.gov/pubmed/35973984 http://dx.doi.org/10.1038/s41421-022-00433-y |
_version_ | 1784769148067250176 |
---|---|
author | Chen, Sisi Chen, Gaoying Xu, Fang Sun, Beibei Chen, Xinyi Hu, Wei Li, Fei Syeda, Madiha Zahra Chen, Haixia Wu, Youqian Wu, Peng Jing, Ruirui Geng, Xinwei Zhang, Lingling Tang, Longguang Li, Wen Chen, Zhihua Zhang, Chao Sun, Jie Chen, Wei Shen, Huahao Ying, Songmin |
author_facet | Chen, Sisi Chen, Gaoying Xu, Fang Sun, Beibei Chen, Xinyi Hu, Wei Li, Fei Syeda, Madiha Zahra Chen, Haixia Wu, Youqian Wu, Peng Jing, Ruirui Geng, Xinwei Zhang, Lingling Tang, Longguang Li, Wen Chen, Zhihua Zhang, Chao Sun, Jie Chen, Wei Shen, Huahao Ying, Songmin |
author_sort | Chen, Sisi |
collection | PubMed |
description | Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immunotherapies demonstrated for the treatment of a variety of malignant tumors, we engineered a cytokine-anchored chimeric antigen receptor T (CCAR-T) cell system using a chimeric IL-5-CD28-CD3ζ receptor to trigger T-cell-mediated killing of eosinophils that are elevated during severe asthma attacks. IL-5-anchored CCAR-T cells exhibited selective and effective killing capacity in vitro and restricted eosinophil differentiation with apparent protection against allergic airway inflammation in two mouse models of asthma. Notably, a single dose of IL-5-anchored CCAR-T cells resulted in persistent protection against asthma-related conditions over three months, significantly exceeding the typical therapeutic window of current mAb-based treatments in the clinics. This study presents a cell-based treatment strategy for SEA and could set the stage for a new era of precision therapies against a variety of intractable allergic diseases in the future. |
format | Online Article Text |
id | pubmed-9381771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-93817712022-08-18 Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells Chen, Sisi Chen, Gaoying Xu, Fang Sun, Beibei Chen, Xinyi Hu, Wei Li, Fei Syeda, Madiha Zahra Chen, Haixia Wu, Youqian Wu, Peng Jing, Ruirui Geng, Xinwei Zhang, Lingling Tang, Longguang Li, Wen Chen, Zhihua Zhang, Chao Sun, Jie Chen, Wei Shen, Huahao Ying, Songmin Cell Discov Article Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immunotherapies demonstrated for the treatment of a variety of malignant tumors, we engineered a cytokine-anchored chimeric antigen receptor T (CCAR-T) cell system using a chimeric IL-5-CD28-CD3ζ receptor to trigger T-cell-mediated killing of eosinophils that are elevated during severe asthma attacks. IL-5-anchored CCAR-T cells exhibited selective and effective killing capacity in vitro and restricted eosinophil differentiation with apparent protection against allergic airway inflammation in two mouse models of asthma. Notably, a single dose of IL-5-anchored CCAR-T cells resulted in persistent protection against asthma-related conditions over three months, significantly exceeding the typical therapeutic window of current mAb-based treatments in the clinics. This study presents a cell-based treatment strategy for SEA and could set the stage for a new era of precision therapies against a variety of intractable allergic diseases in the future. Springer Nature Singapore 2022-08-16 /pmc/articles/PMC9381771/ /pubmed/35973984 http://dx.doi.org/10.1038/s41421-022-00433-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chen, Sisi Chen, Gaoying Xu, Fang Sun, Beibei Chen, Xinyi Hu, Wei Li, Fei Syeda, Madiha Zahra Chen, Haixia Wu, Youqian Wu, Peng Jing, Ruirui Geng, Xinwei Zhang, Lingling Tang, Longguang Li, Wen Chen, Zhihua Zhang, Chao Sun, Jie Chen, Wei Shen, Huahao Ying, Songmin Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells |
title | Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells |
title_full | Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells |
title_fullStr | Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells |
title_full_unstemmed | Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells |
title_short | Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells |
title_sort | treatment of allergic eosinophilic asthma through engineered il-5-anchored chimeric antigen receptor t cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381771/ https://www.ncbi.nlm.nih.gov/pubmed/35973984 http://dx.doi.org/10.1038/s41421-022-00433-y |
work_keys_str_mv | AT chensisi treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT chengaoying treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT xufang treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT sunbeibei treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT chenxinyi treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT huwei treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT lifei treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT syedamadihazahra treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT chenhaixia treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT wuyouqian treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT wupeng treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT jingruirui treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT gengxinwei treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT zhanglingling treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT tanglongguang treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT liwen treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT chenzhihua treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT zhangchao treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT sunjie treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT chenwei treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT shenhuahao treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells AT yingsongmin treatmentofallergiceosinophilicasthmathroughengineeredil5anchoredchimericantigenreceptortcells |